Picture of Zai Lab logo

ZLAB — Zai Lab News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Brief: Zai Lab Announces First Patient Treated In Mainland China For Study Of Bemarituzumab

July 14 (Reuters) - Zai Lab Ltd  9688.HK :
    * ZAI LAB ANNOUNCES FIRST PATIENT TREATED IN MAINLAND CHINA
FOR
THE GLOBAL PHASE 3 FORTITUDE-101 STUDY OF BEMARITUZUMAB IN
FIRST-LINE GASTRIC CANCER
    * ZAI LAB LTD - IN EARLY 2024, ZAI LAB WILL JOIN
AMGEN-SPONSORED
GLOBAL PHASE 3 FORTITUDE-102 STUDY IN FIRST-LINE GASTRIC CANCER

Source text for Eikon:  ID:nGNXbhW1YH 
Further company coverage:  9688.HK 

 ((Reuters.Briefs@thomsonreuters.com;))

Recent news on Zai Lab

See all news